VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH CML 2022 | Combining autophagy inhibitors with TKIs in CML

Vignir Helgason, PhD, University of Glasgow, Glasgow, UK, comments on the possibility of combining autophagy inhibitors with tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter